The global COX-2 Selective NSAIDs market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.

Nonsteroidal anti-inflammatory drugs (NSAIDs) have analgesic, antipyretic and anti-inflammatory effects, but can also cause a series of adverse reactions. Their mechanism of action is mainly to inhibit cyclooxygenase [cyclooxygenase, COX; also known as prostaglandin synthase (PGHS)], preventing the conversion of arachidonic acid into various prostaglandins, prostacyclins and thromboxanes. COX has two isoenzymes, COX-1 and COX-2, and there are significant differences in the regulation and expression of the two in different tissues. Various NSAIDs have different enzyme inhibition abilities, which can affect their activity and toxicity at the same time. Before the discovery of the COX-2 isoenzyme in the early 1990s, most NSAIDs could effectively inhibit both COXs. However, researchers later developed NSAIDs that can preferentially inhibit COX-2 while retaining the activity of COX-1. COX-2 is in the inflammatory mediators and participates in the production of inflammatory mediators, while COX-1 has an important gastric cell protective effect. The new drugs are called COX-2 selective NSAIDs (COXIBs), also known as COX-2 inhibitors and COX-2 selective inhibitors.

From a downstream perspective, Hospital accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).

COX-2 Selective NSAIDs leading manufacturers including Pfizer, Teva, Mylan, Apotex, Lupin, Jiangsu Hengrui Medicine, Merck, etc., dominate supply; the top five capture approximately % of global revenue, with Pfizer leading 2024 sales at US$ million.

Regional Outlook:

North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).

Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).

Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global COX-2 Selective NSAIDs market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.

By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.

Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.

Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.

Market Segmentation

Scope of COX-2 Selective NSAIDs Market Report

Report Metric	Details
Report Name	COX-2 Selective NSAIDs Market
Segment by Type	Celecoxib Rofecoxib Valdecoxib Etoricoxib
Segment by Application	Hospital Clinic Other
Sales by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Pfizer, Teva, Mylan, Apotex, Lupin, Jiangsu Hengrui Medicine, Merck
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the COX-2 Selective NSAIDs study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the COX-2 Selective NSAIDs Market report?

Ans: The main players in the COX-2 Selective NSAIDs Market are Pfizer, Teva, Mylan, Apotex, Lupin, Jiangsu Hengrui Medicine, Merck

What are the Application segmentation covered in the COX-2 Selective NSAIDs Market report?

Ans: The Applications covered in the COX-2 Selective NSAIDs Market report are Hospital, Clinic, Other

What are the Type segmentation covered in the COX-2 Selective NSAIDs Market report?

Ans: The Types covered in the COX-2 Selective NSAIDs Market report are Celecoxib, Rofecoxib, Valdecoxib, Etoricoxib

1 Study Coverage

1.1 Introduction to COX-2 Selective NSAIDs: Definition, Properties, and Key Attributes

1.2 Market Segmentation by Type

1.2.1 Global COX-2 Selective NSAIDs Market Size by Type, 2020 VS 2024 VS 2031

1.2.2 Celecoxib

1.2.3 Rofecoxib

1.2.4 Valdecoxib

1.2.5 Etoricoxib

1.3 Market Segmentation by Application

1.3.1 Global COX-2 Selective NSAIDs Market Size by Application, 2020 VS 2024 VS 2031

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Other

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Executive Summary

2.1 Global COX-2 Selective NSAIDs Revenue Estimates and Forecasts 2020-2031

2.2 Global COX-2 Selective NSAIDs Revenue by Region

2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031

2.2.2 Historical and Forecasted Revenue by Region (2020--2031)

2.2.3 Global Revenue Market Share by Region (2020-2031)

2.3 Global COX-2 Selective NSAIDs Sales Estimates and Forecasts 2020-2031

2.4 Global COX-2 Selective NSAIDs Sales by Region

2.4.1 Sales Comparison: 2020 VS 2024 VS 2031

2.4.2 Historical and Forecasted Sales by Region (2020-2031)

2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends

2.4.4 Global Sales Market Share by Region (2020-2031)

3 Competition by Manufacturers

3.1 Global COX-2 Selective NSAIDs Sales by Manufacturers

3.1.1 Global Sales Volume by Manufacturers (2020-2025)

3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)

3.2 Global COX-2 Selective NSAIDs Manufacturer Revenue Rankings and Tiers

3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)

3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)

3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)

3.3 Manufacturer Profitability Profiles and Pricing Strategies

3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)

3.3.2 Manufacturer-Level Price Trends (2020-2025)

3.4 Key Manufacturers Manufacturing Base and Headquarters

3.5 Main Product Type Market Size by Manufacturers

3.5.1 Celecoxib Market Size by Manufacturers

3.5.2 Rofecoxib Market Size by Manufacturers

3.5.3 Valdecoxib Market Size by Manufacturers

3.5.4 Etoricoxib Market Size by Manufacturers

3.6 Global COX-2 Selective NSAIDs Market Concentration and Dynamics

3.6.1 Global Market Concentration (CR5 and HHI)

3.6.2 Entrant/Exit Impact Analysis

3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment

4 Global Product Segmentation Analysis

4.1 Global COX-2 Selective NSAIDs Sales Performance by Type

4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)

4.1.2 Global Sales Market Share by Type (2020-2031)

4.2 Global COX-2 Selective NSAIDs Revenue Trends by Type

4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)

4.2.2 Global Revenue Market Share by Type (2020-2031)

4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)

4.4 Product Technology Differentiation

4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk

4.5.1 High-Growth Niches and Adoption Drivers

4.5.2 Profitability Hotspots and Cost Drivers

4.5.3 Substitution Threats

5 Global Downstream Application Analysis

5.1 Global COX-2 Selective NSAIDs Sales by Application

5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)

5.1.2 Global Sales Market Share by Application (2020-2031)

5.1.3 High-Growth Application Identification

5.1.4 Emerging Application Case Studies

5.2 Global COX-2 Selective NSAIDs Revenue by Application

5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)

5.2.2 Revenue Market Share by Application (2020-2031)

5.3 Global Pricing Dynamics by Application (2020-2031)

5.4 Downstream Customer Analysis

5.4.1 Top Customers by Region

5.4.2 Top Customers by Application

6 North America

6.1 North America Sales Volume and Revenue (2020-2031)

6.2 North America Key Manufacturers Sales Revenue in 2024

6.3 North America COX-2 Selective NSAIDs Sales and Revenue by Type (2020-2031)

6.4 North America COX-2 Selective NSAIDs Sales and Revenue by Application (2020-2031)

6.5 North America Growth Accelerators and Market Barriers

6.6 North America COX-2 Selective NSAIDs Market Size by Country

6.6.1 North America Revenue by Country

6.6.2 North America Sales Trends by Country

6.6.3 US

6.6.4 Canada

6.6.5 Mexico

7 Europe

7.1 Europe Sales Volume and Revenue (2020-2031)

7.2 Europe Key Manufacturers Sales Revenue in 2024

7.3 Europe COX-2 Selective NSAIDs Sales and Revenue by Type (2020-2031)

7.4 Europe COX-2 Selective NSAIDs Sales and Revenue by Application (2020-2031)

7.5 Europe Growth Accelerators and Market Barriers

7.6 Europe COX-2 Selective NSAIDs Market Size by Country

7.6.1 Europe Revenue by Country

7.6.2 Europe Sales Trends by Country

7.6.3 Germany

7.6.4 France

7.6.5 U.K.

7.6.6 Italy

7.6.7 Russia

8 Asia-Pacific

8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)

8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024

8.3 Asia-Pacific COX-2 Selective NSAIDs Sales and Revenue by Type (2020-2031)

8.4 Asia-Pacific COX-2 Selective NSAIDs Sales and Revenue by Application (2020-2031)

8.5 Asia-Pacific COX-2 Selective NSAIDs Market Size by Region

8.5.1 Asia-Pacific Revenue by Region

8.5.2 Asia-Pacific Sales Trends by Region

8.6 Asia-Pacific Growth Accelerators and Market Barriers

8.7 Southeast Asia

8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)

8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines

8.8 China

8.9 Japan

8.10 South Korea

8.11 China Taiwan

8.12 India

9 Central and South America

9.1 Central and South America Sales Volume and Revenue (2020-2031)

9.2 Central and South America Key Manufacturers Sales Revenue in 2024

9.3 Central and South America COX-2 Selective NSAIDs Sales and Revenue by Type (2020-2031)

9.4 Central and South America COX-2 Selective NSAIDs Sales and Revenue by Application (2020-2031)

9.5 Central and South America Investment Opportunities and Key Challenges

9.6 Central and South America COX-2 Selective NSAIDs Market Size by Country

9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)

9.6.2 Brazil

9.6.3 Argentina

10 Middle East and Africa

10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)

10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024

10.3 Middle East and Africa COX-2 Selective NSAIDs Sales and Revenue by Type (2020-2031)

10.4 Middle East and Africa COX-2 Selective NSAIDs Sales and Revenue by Application (2020-2031)

10.5 Middle East and Africa Investment Opportunities and Key Challenges

10.6 Middle East and Africa COX-2 Selective NSAIDs Market Size by Country

10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)

10.6.2 GCC Countries

10.6.3 Turkey

10.6.4 Egypt

10.6.5 South Africa

11 Corporate Profile

11.1 Pfizer

11.1.1 Pfizer Corporation Information

11.1.2 Pfizer Business Overview

11.1.3 Pfizer COX-2 Selective NSAIDs Product Models, Descriptions and Specifications

11.1.4 Pfizer COX-2 Selective NSAIDs Sales, Price, Revenue and Gross Margin (2020-2025)

11.1.5 Pfizer COX-2 Selective NSAIDs Sales by Product in 2024

11.1.6 Pfizer COX-2 Selective NSAIDs Sales by Application in 2024

11.1.7 Pfizer COX-2 Selective NSAIDs Sales by Geographic Area in 2024

11.1.8 Pfizer COX-2 Selective NSAIDs SWOT Analysis

11.1.9 Pfizer Recent Developments

11.2 Teva

11.2.1 Teva Corporation Information

11.2.2 Teva Business Overview

11.2.3 Teva COX-2 Selective NSAIDs Product Models, Descriptions and Specifications

11.2.4 Teva COX-2 Selective NSAIDs Sales, Price, Revenue and Gross Margin (2020-2025)

11.2.5 Teva COX-2 Selective NSAIDs Sales by Product in 2024

11.2.6 Teva COX-2 Selective NSAIDs Sales by Application in 2024

11.2.7 Teva COX-2 Selective NSAIDs Sales by Geographic Area in 2024

11.2.8 Teva COX-2 Selective NSAIDs SWOT Analysis

11.2.9 Teva Recent Developments

11.3 Mylan

11.3.1 Mylan Corporation Information

11.3.2 Mylan Business Overview

11.3.3 Mylan COX-2 Selective NSAIDs Product Models, Descriptions and Specifications

11.3.4 Mylan COX-2 Selective NSAIDs Sales, Price, Revenue and Gross Margin (2020-2025)

11.3.5 Mylan COX-2 Selective NSAIDs Sales by Product in 2024

11.3.6 Mylan COX-2 Selective NSAIDs Sales by Application in 2024

11.3.7 Mylan COX-2 Selective NSAIDs Sales by Geographic Area in 2024

11.3.8 Mylan COX-2 Selective NSAIDs SWOT Analysis

11.3.9 Mylan Recent Developments

11.4 Apotex

11.4.1 Apotex Corporation Information

11.4.2 Apotex Business Overview

11.4.3 Apotex COX-2 Selective NSAIDs Product Models, Descriptions and Specifications

11.4.4 Apotex COX-2 Selective NSAIDs Sales, Price, Revenue and Gross Margin (2020-2025)

11.4.5 Apotex COX-2 Selective NSAIDs Sales by Product in 2024

11.4.6 Apotex COX-2 Selective NSAIDs Sales by Application in 2024

11.4.7 Apotex COX-2 Selective NSAIDs Sales by Geographic Area in 2024

11.4.8 Apotex COX-2 Selective NSAIDs SWOT Analysis

11.4.9 Apotex Recent Developments

11.5 Lupin

11.5.1 Lupin Corporation Information

11.5.2 Lupin Business Overview

11.5.3 Lupin COX-2 Selective NSAIDs Product Models, Descriptions and Specifications

11.5.4 Lupin COX-2 Selective NSAIDs Sales, Price, Revenue and Gross Margin (2020-2025)

11.5.5 Lupin COX-2 Selective NSAIDs Sales by Product in 2024

11.5.6 Lupin COX-2 Selective NSAIDs Sales by Application in 2024

11.5.7 Lupin COX-2 Selective NSAIDs Sales by Geographic Area in 2024

11.5.8 Lupin COX-2 Selective NSAIDs SWOT Analysis

11.5.9 Lupin Recent Developments

11.6 Jiangsu Hengrui Medicine

11.6.1 Jiangsu Hengrui Medicine Corporation Information

11.6.2 Jiangsu Hengrui Medicine Business Overview

11.6.3 Jiangsu Hengrui Medicine COX-2 Selective NSAIDs Product Models, Descriptions and Specifications

11.6.4 Jiangsu Hengrui Medicine COX-2 Selective NSAIDs Sales, Price, Revenue and Gross Margin (2020-2025)

11.6.5 Jiangsu Hengrui Medicine Recent Developments

11.7 Merck

11.7.1 Merck Corporation Information

11.7.2 Merck Business Overview

11.7.3 Merck COX-2 Selective NSAIDs Product Models, Descriptions and Specifications

11.7.4 Merck COX-2 Selective NSAIDs Sales, Price, Revenue and Gross Margin (2020-2025)

11.7.5 Merck Recent Developments

12 Value Chain and Supply-Chain Analysis

12.1 COX-2 Selective NSAIDs Industry Chain

12.2 COX-2 Selective NSAIDs Upstream Materials Analysis

12.2.1 Raw Materials

12.2.2 Key Suppliers Market Share & Risk Assessment

12.3 COX-2 Selective NSAIDs Integrated Production Analysis

12.3.1 Manufacturing Footprint Analysis

12.3.2 Regional Production Market Share (2020-2031)

12.3.3 Regulatory and Trade Policy Impact on Production

12.3.4 Production Technology Overview

12.3.5 Regional Cost Drivers

12.4 COX-2 Selective NSAIDs Sales Channels and Distribution Networks

12.4.1 Sales Channels

12.4.2 Distributors

13 COX-2 Selective NSAIDs Market Dynamics

13.1 Industry Trends and Evolution

13.2 Market Growth Drivers and Emerging Opportunities

13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global COX-2 Selective NSAIDs Study

15 Appendix

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.1.1 Research Programs/Design

15.1.1.2 Market Size Estimation

15.1.1.3 Market Breakdown and Data Triangulation

15.1.2 Data Source

15.1.2.1 Secondary Sources

15.1.2.2 Primary Sources

15.2 Author Details

FEATURED COMPANIES

Jiangsu Hengrui Medicine

Merck

List of Tables

Table 1. Global COX-2 Selective NSAIDs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Table 2. Global COX-2 Selective NSAIDs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Table 3. Global COX-2 Selective NSAIDs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 4. Global COX-2 Selective NSAIDs Revenue by Region (2020-2025) & (US$ Million)

Table 5. Global COX-2 Selective NSAIDs Revenue by Region (2026-2031) & (US$ Million)

Table 6. Global COX-2 Selective NSAIDs Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)

Table 7. Global COX-2 Selective NSAIDs Sales by Region (2020-2025) & (K Units)

Table 8. Global COX-2 Selective NSAIDs Sales by Region (2026-2031) & (K Units)

Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 10. Global COX-2 Selective NSAIDs Sales by Manufacturers (2020-2025) & (K Units)

Table 11. Global COX-2 Selective NSAIDs Sales Share by Manufacturers (2020-2025)

Table 12. Global COX-2 Selective NSAIDs Revenue by Manufacturers (2020-2025) & (US$ Million)

Table 13. Global COX-2 Selective NSAIDs Revenue Market Share by Manufacturers (2020-2025)

Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)

Table 15. Global COX-2 Selective NSAIDs by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in COX-2 Selective NSAIDs as of 2024)

Table 16. Global COX-2 Selective NSAIDs Average Gross Margin (%) by Manufacturer (2020 VS 2024)

Table 17. Global COX-2 Selective NSAIDs Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)

Table 18. Key Manufacturers COX-2 Selective NSAIDs Manufacturing Base and Headquarters

Table 19. Global COX-2 Selective NSAIDs Market Concentration Ratio (CR5 and HHI)

Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis

Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment

Table 22. Global COX-2 Selective NSAIDs Sales by Type (2020-2025) & (K Units)

Table 23. Global COX-2 Selective NSAIDs Sales by Type (2026-2031) & (K Units)

Table 24. Global COX-2 Selective NSAIDs Revenue by Type (2020-2025) & (US$ Million)

Table 25. Global COX-2 Selective NSAIDs Revenue by Type (2026-2031) & (US$ Million)

Table 26. Global COX-2 Selective NSAIDs ASP by Type (2020-2031) & (US$/Unit)

Table 27. Technical Specifications by Key Product Type

Table 28. Global COX-2 Selective NSAIDs Sales by Application (2020-2025) & (K Units)

Table 29. Global COX-2 Selective NSAIDs Sales by Application (2026-2031) & (K Units)

Table 30. COX-2 Selective NSAIDs High-Growth Sectors Demand CAGR (2024-2031)

Table 31. Global COX-2 Selective NSAIDs Revenue by Application (2020-2025) & (US$ Million)

Table 32. Global COX-2 Selective NSAIDs Revenue by Application (2026-2031) & (US$ Million)

Table 33. Global COX-2 Selective NSAIDs ASP by Application (2020-2031) & (US$/Unit)

Table 34. Top Customers by Region

Table 35. Top Customers by Application

Table 36. North America COX-2 Selective NSAIDs Growth Accelerators and Market Barriers

Table 37. North America COX-2 Selective NSAIDs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 38. North America COX-2 Selective NSAIDs Sales (K Units) by Country (2020 VS 2024 VS 2031)

Table 39. Europe COX-2 Selective NSAIDs Growth Accelerators and Market Barriers

Table 40. Europe COX-2 Selective NSAIDs Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Europe COX-2 Selective NSAIDs Sales (K Units) by Country (2020 VS 2024 VS 2031)

Table 42. Asia-Pacific COX-2 Selective NSAIDs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 43. Asia-Pacific COX-2 Selective NSAIDs Sales (K Units) by Country (2020 VS 2024 VS 2031)

Table 44. Asia-Pacific COX-2 Selective NSAIDs Growth Accelerators and Market Barriers

Table 45. Southeast Asia COX-2 Selective NSAIDs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Central and South America COX-2 Selective NSAIDs Investment Opportunities and Key Challenges

Table 47. Central and South America COX-2 Selective NSAIDs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 48. Middle East and Africa COX-2 Selective NSAIDs Investment Opportunities and Key Challenges

Table 49. Middle East and Africa COX-2 Selective NSAIDs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 50. Pfizer Corporation Information

Table 51. Pfizer Description and Major Businesses

Table 52. Pfizer Product Models, Descriptions and Specifications

Table 53. Pfizer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 54. Pfizer Sales Value Proportion by Product in 2024

Table 55. Pfizer Sales Value Proportion by Application in 2024

Table 56. Pfizer Sales Value Proportion by Geographic Area in 2024

Table 57. Pfizer COX-2 Selective NSAIDs SWOT Analysis

Table 58. Pfizer Recent Developments

Table 59. Teva Corporation Information

Table 60. Teva Description and Major Businesses

Table 61. Teva Product Models, Descriptions and Specifications

Table 62. Teva Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 63. Teva Sales Value Proportion by Product in 2024

Table 64. Teva Sales Value Proportion by Application in 2024

Table 65. Teva Sales Value Proportion by Geographic Area in 2024

Table 66. Teva COX-2 Selective NSAIDs SWOT Analysis

Table 67. Teva Recent Developments

Table 68. Mylan Corporation Information

Table 69. Mylan Description and Major Businesses

Table 70. Mylan Product Models, Descriptions and Specifications

Table 71. Mylan Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 72. Mylan Sales Value Proportion by Product in 2024

Table 73. Mylan Sales Value Proportion by Application in 2024

Table 74. Mylan Sales Value Proportion by Geographic Area in 2024

Table 75. Mylan COX-2 Selective NSAIDs SWOT Analysis

Table 76. Mylan Recent Developments

Table 77. Apotex Corporation Information

Table 78. Apotex Description and Major Businesses

Table 79. Apotex Product Models, Descriptions and Specifications

Table 80. Apotex Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 81. Apotex Sales Value Proportion by Product in 2024

Table 82. Apotex Sales Value Proportion by Application in 2024

Table 83. Apotex Sales Value Proportion by Geographic Area in 2024

Table 84. Apotex COX-2 Selective NSAIDs SWOT Analysis

Table 85. Apotex Recent Developments

Table 86. Lupin Corporation Information

Table 87. Lupin Description and Major Businesses

Table 88. Lupin Product Models, Descriptions and Specifications

Table 89. Lupin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 90. Lupin Sales Value Proportion by Product in 2024

Table 91. Lupin Sales Value Proportion by Application in 2024

Table 92. Lupin Sales Value Proportion by Geographic Area in 2024

Table 93. Lupin COX-2 Selective NSAIDs SWOT Analysis

Table 94. Lupin Recent Developments

Table 95. Jiangsu Hengrui Medicine Corporation Information

Table 96. Jiangsu Hengrui Medicine Description and Major Businesses

Table 97. Jiangsu Hengrui Medicine Product Models, Descriptions and Specifications

Table 98. Jiangsu Hengrui Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 99. Jiangsu Hengrui Medicine Recent Developments

Table 100. Merck Corporation Information

Table 101. Merck Description and Major Businesses

Table 102. Merck Product Models, Descriptions and Specifications

Table 103. Merck Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 104. Merck Recent Developments

Table 105. Key Raw Materials Distribution

Table 106. Raw Materials Key Suppliers

Table 107. Critical Raw Material Supplier Concentration (2024) & Risk Index

Table 108. Milestones in Production Technology Evolution

Table 109. Distributors List

Table 110. Market Trends and Market Evolution

Table 111. Market Drivers and Opportunities

Table 112. Market Challenges, Risks, and Restraints

Table 113. Research Programs/Design for This Report

Table 114. Key Data Information from Secondary Sources

Table 115. Key Data Information from Primary Sources

List of Figures

Figure 1. COX-2 Selective NSAIDs Product Picture

Figure 2. Global COX-2 Selective NSAIDs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Figure 3. Celecoxib Product Picture

Figure 4. Rofecoxib Product Picture

Figure 5. Valdecoxib Product Picture

Figure 6. Etoricoxib Product Picture

Figure 7. Global COX-2 Selective NSAIDs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Figure 8. Hospital

Figure 9. Clinic

Figure 10. Other

Figure 11. COX-2 Selective NSAIDs Report Years Considered

Figure 12. Global COX-2 Selective NSAIDs Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 13. Global COX-2 Selective NSAIDs Revenue (2020-2031) & (US$ Million)

Figure 14. Global COX-2 Selective NSAIDs Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Figure 15. Global COX-2 Selective NSAIDs Revenue Market Share by Region (2020-2031)

Figure 16. Global COX-2 Selective NSAIDs Sales (2020-2031) & (K Units)

Figure 17. Global COX-2 Selective NSAIDs Sales (CAGR) by Region (2020-2031) (K Units)

Figure 18. Global COX-2 Selective NSAIDs Sales Market Share by Region (2020-2031)

Figure 19. Top 5 and Top 10 Manufacturers COX-2 Selective NSAIDs Sales Volume Market Share in 2024

Figure 20. Global COX-2 Selective NSAIDs Revenue Market Share Ranking (2024)

Figure 21. Tier Distribution by Revenue Contribution (2020 VS 2024)

Figure 22. Celecoxib Revenue Market Share by Manufacturer in 2024

Figure 23. Rofecoxib Revenue Market Share by Manufacturer in 2024

Figure 24. Valdecoxib Revenue Market Share by Manufacturer in 2024

Figure 25. Etoricoxib Revenue Market Share by Manufacturer in 2024

Figure 26. Global COX-2 Selective NSAIDs Sales Market Share by Type (2020-2031)

Figure 27. Global COX-2 Selective NSAIDs Revenue Market Share by Type (2020-2031)

Figure 28. Global COX-2 Selective NSAIDs Sales Market Share by Application (2020-2031)

Figure 29. Global COX-2 Selective NSAIDs Revenue Market Share by Application (2020-2031)

Figure 30. North America COX-2 Selective NSAIDs Sales YoY (2020-2031) & (K Units)

Figure 31. North America COX-2 Selective NSAIDs Revenue YoY (2020-2031) & (US$ Million)

Figure 32. North America Top 5 Manufacturers COX-2 Selective NSAIDs Sales Revenue (US$ Million) in 2024

Figure 33. North America COX-2 Selective NSAIDs Sales Volume (K Units) by Type (2020- 2031)

Figure 34. North America COX-2 Selective NSAIDs Sales Revenue (US$ Million) by Type (2020 - 2031)

Figure 35. North America COX-2 Selective NSAIDs Sales Volume (K Units) by Application (2020-2031)

Figure 36. North America COX-2 Selective NSAIDs Sales Revenue (US$ Million) by Application (2020-2031)

Figure 37. US COX-2 Selective NSAIDs Revenue (2020-2031) & (US$ Million)

Figure 38. Canada COX-2 Selective NSAIDs Revenue (2020-2031) & (US$ Million)

Figure 39. Mexico COX-2 Selective NSAIDs Revenue (2020-2031) & (US$ Million)

Figure 40. Europe COX-2 Selective NSAIDs Sales YoY (2020-2031) & (K Units)

Figure 41. Europe COX-2 Selective NSAIDs Revenue YoY (2020-2031) & (US$ Million)

Figure 42. Europe Top 5 Manufacturers COX-2 Selective NSAIDs Sales Revenue (US$ Million) in 2024

Figure 43. Europe COX-2 Selective NSAIDs Sales Volume (K Units) by Type (2020-2031)

Figure 44. Europe COX-2 Selective NSAIDs Sales Revenue (US$ Million) by Type (2020-2031)

Figure 45. Europe COX-2 Selective NSAIDs Sales Volume (K Units) by Application (2020-2031)

Figure 46. Europe COX-2 Selective NSAIDs Sales Revenue (US$ Million) by Application (2020-2031)

Figure 47. Germany COX-2 Selective NSAIDs Revenue (2020-2031) & (US$ Million)

Figure 48. France COX-2 Selective NSAIDs Revenue (2020-2031) & (US$ Million)

Figure 49. U.K. COX-2 Selective NSAIDs Revenue (2020-2031) & (US$ Million)

Figure 50. Italy COX-2 Selective NSAIDs Revenue (2020-2031) & (US$ Million)

Figure 51. Russia COX-2 Selective NSAIDs Revenue (2020-2031) & (US$ Million)

Figure 52. Asia-Pacific COX-2 Selective NSAIDs Sales YoY (2020-2031) & (K Units)

Figure 53. Asia-Pacific COX-2 Selective NSAIDs Revenue YoY (2020-2031) & (US$ Million)

Figure 54. Asia-Pacific Top 8 Manufacturers COX-2 Selective NSAIDs Sales Revenue (US$ Million) in 2024

Figure 55. Asia-Pacific COX-2 Selective NSAIDs Sales Volume (K Units) by Type (2020- 2031)

Figure 56. Asia-Pacific COX-2 Selective NSAIDs Sales Revenue (US$ Million) by Type (2020- 2031)

Figure 57. Asia-Pacific COX-2 Selective NSAIDs Sales Volume (K Units) by Application (2020-2031)

Figure 58. Asia-Pacific COX-2 Selective NSAIDs Sales Revenue (US$ Million) by Application (2020-2031)

Figure 59. Indonesia COX-2 Selective NSAIDs Revenue (2020-2031) & (US$ Million)

Figure 60. Japan COX-2 Selective NSAIDs Revenue (2020-2031) & (US$ Million)

Figure 61. South Korea COX-2 Selective NSAIDs Revenue (2020-2031) & (US$ Million)

Figure 62. China Taiwan COX-2 Selective NSAIDs Revenue (2020-2031) & (US$ Million)

Figure 63. India COX-2 Selective NSAIDs Revenue (2020-2031) & (US$ Million)

Figure 64. Central and South America COX-2 Selective NSAIDs Sales YoY (2020-2031) & (K Units)

Figure 65. Central and South America COX-2 Selective NSAIDs Revenue YoY (2020-2031) & (US$ Million)

Figure 66. Central and South America Top 5 Manufacturers COX-2 Selective NSAIDs Sales Revenue (US$ Million) in 2024

Figure 67. Central and South America COX-2 Selective NSAIDs Sales Volume (K Units) by Type (2021-2031)

Figure 68. Central and South America COX-2 Selective NSAIDs Sales Revenue (US$ Million) by Type (2020-2031)

Figure 69. Central and South America COX-2 Selective NSAIDs Sales Volume (K Units) by Application (2020-2031)

Figure 70. Central and South America COX-2 Selective NSAIDs Sales Revenue (US$ Million) by Application (2020-2031)

Figure 71. Brazil COX-2 Selective NSAIDs Revenue (2020-2025) & (US$ Million)

Figure 72. Argentina COX-2 Selective NSAIDs Revenue (2020-2025) & (US$ Million)

Figure 73. Middle East, and Africa COX-2 Selective NSAIDs Sales YoY (2020-2031) & (K Units)

Figure 74. Middle East and Africa COX-2 Selective NSAIDs Revenue YoY (2020-2031) & (US$ Million)

Figure 75. Middle East and Africa Top 5 Manufacturers COX-2 Selective NSAIDs Sales Revenue (US$ Million) in 2024

Figure 76. Middle East and Africa COX-2 Selective NSAIDs Sales Volume (K Units) by Type (2021-2031)

Figure 77. South America COX-2 Selective NSAIDs Sales Revenue (US$ Million) by Type (2020-2031)

Figure 78. Middle East and Africa COX-2 Selective NSAIDs Sales Volume (K Units) by Application (2020-2031)

Figure 79. Middle East and Africa COX-2 Selective NSAIDs Sales Revenue (US$ Million) by Application (2020-2031)

Figure 80. GCC Countries COX-2 Selective NSAIDs Revenue (2020-2025) & (US$ Million)

Figure 81. Turkey COX-2 Selective NSAIDs Revenue (2020-2025) & (US$ Million)

Figure 82. Egypt COX-2 Selective NSAIDs Revenue (2020-2025) & (US$ Million)

Figure 83. South Africa COX-2 Selective NSAIDs Revenue (2020-2025) & (US$ Million)

Figure 84. COX-2 Selective NSAIDs Industry Chain Mapping

Figure 85. Regional COX-2 Selective NSAIDs Manufacturing Base Distribution (%)

Figure 86. Global COX-2 Selective NSAIDs Production Market Share by Region (2020-2031)

Figure 87. COX-2 Selective NSAIDs Production Process

Figure 88. Regional COX-2 Selective NSAIDs Production Cost Structure

Figure 89. Channels of Distribution (Direct Vs Distribution)

Figure 90. Bottom-up and Top-down Approaches for This Report

Figure 91. Data Triangulation

Figure 92. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$4900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions